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Abstract
Background: Intermittent preventive treatment in infants (IPTi) with sulphadoxine-pyrimethamine (SP) given during
routine vaccinations is efficacious in preventing malaria disease and shows no interaction with the vaccines.
However, there is a fear that IPTi may result in a rapid increase of parasite resistance to SP.
Methods: To evaluate the impact of IPTi on SP-resistance point mutations, the 22 health sub-districts in the district
of Kolokani, Mali, were randomized in a 1:1 ratio and starting in December 2006, IPTi with SP was implemented in
11 health sub-districts (intervention zone), while the other 11 health sub-districts served as the control (non-
intervention zone). Blood smears and blood dots on filter paper were obtained from children aged 0-5 years,
randomly selected in each of heath sub-districts during two cross-sectional surveys. The first survey was conducted
in May 2007 before the start of the transmission season to collect baseline prevalence of the molecular markers of
resistance to SP and the second in December 2007 after the end of the transmission season and one year after
implementation of IPTi. A total of 427 and 923 randomly selected blood samples from the first and second surveys
respectively were analysed by PCR for dhfr and dhps mutations.
Results: Each of the three dhfr mutations at codons 51, 59 and 108 was present in 35% and 57% of the samples
during the two surveys with no significant differences between the two zones. Dhps mutations at codons 437 and
540 were present respectively in about 20% and 1% of the children during the two surveys in both zones at
similar proportion. The prevalence of quadruple mutants (triple dhfr-mutants + dhps-437G) associated with in-vivo
resistance to SP in Mali after one year implementation of IPTi was also similar between the two zones (11.6%
versus 11.2%, p = 0.90) and to those obtained at baseline survey (10.3% versus 8.1%).
Conclusion: This study shows no increase in the frequency of molecular markers of SP resistance in areas where
IPTi with SP was implemented for one year.
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Malaria remains a major cause of morbidity and mortal-
ity with an estimate of 881,000 deaths per year of which
91% occur in sub-Saharan Africa, mainly in infants and
children under five years of age [1]. In the absence of a
vaccine, simple and effective control strategies are
urgently needed to reduce the malaria burden in sub-
Saharan Africa. Several randomized controlled trials
have demonstrated that Intermittent Preventive Treat-
ment of malaria in infants (IPTi) with sulphadoxine-pyr-
imethamine (SP) given during routine vaccinations of
the Expanded Programme of Immunization (EPI) at
approximately two, three and nine months of age, result
i nar e d u c t i o no ft h ei n c i d e n c eo fc l i n i c a lm a l a r i ab y2 2
to 59% [2-8], without showing interactions with EPI vac-
cines [2,4,9]. Although the efficacy and safety as well as
the lack of interaction with EPI vaccines of IPTi in var-
ious endemic areas were well established [10-12], there
have been concerns regarding the possibility that this
strategy may cause an increase of Plasmodium falci-
parum resistance to SP, jeopardizing the use of SP not
only for the prevention of malaria in infants, but also in
pregnant women [13-15], an intervention widely
adopted in many countries in sub-Saharan Africa. SP is
known to rapidly select for mutant SP-resistant parasites
[16-19], especially when given in prophylaxis, despite
the reassuring predictions from mathematical modeling
[13,20]. A report on the impact of IPTi with SP on the
resistance of P. falciparum to SP in Mozambican chil-
dren found no difference in the frequencies of dhfr and
dhps mutations in children with a clinical malaria epi-
sode two months after the third dose of IPTi [21]. How-
ever, this study was conducted in the context of a
placebo-controlled randomized trial with a limited num-
ber (n = 174) of samples. An evaluation in a context of
large-scale implementation was needed to adequately
address the impact of IPTi on SP drug resistance. This
study evaluated the impact of IPTi on the selection SP-
resistant dhfr and dhps mutations in P. falciparum after
12 months of implementation of IPTi in the district of
Kolokani, Mali, where UNICEF pilot implementation of
IPTi with SP was undertaken as part of a large opera-




The study was conducted in the district of Kolokani,
Mali. The district of Kolokani is an administrative sub-
division of the region of Koulikoro. The town of Kolo-
kani is located approximately 140 km north of Bamako.
The district covers 14,380 km
2 and is divided into 22
health sub-districts. Each health sub-district is
composed of several villages and has a health care cen-
ter under the responsibility of a physician or chief-nurse
and is staffed with at least two or three midwives and
vaccinators. Three physicians ensure the coordination of
health activities at the district level. The total population
was 214,509 inhabitants. The children under one year of
age represent about 4% of the total population. Malaria
transmission is seasonal (July to November) with para-
site prevalence in children 0-5 years of 45% at the end
of the no-transmission season and above 70% at the end
of the transmission season. First-line treatment of
uncomplicated malaria was artesunate-amodiaquine or
artemether-lumefantrine. Quinine was recommended for
the treatment of severe malaria and SP was recom-
mended prophylaxis for pregnant women.
Study participants and design
The study was a cluster-randomized trial. Twenty-two
health sub-districts were randomized into two groups in
a 1:1 ratio and IPTi was implemented in 11 health sub-
districts (intervention zone) while the other 11 health
sub-districts served as the control (non-intervention
zone). The implementation of IPTi started in December
2006 and consisted of the administration of ½ tablet of
SP alongside the DTP2, DTP3 and Measles routine
immunizations. Afridoxine® (manufactured by Fourrts
Laboratories Pvt. Ltd, Tamil Nadu, India), a breakable
and dispersible form of SP was used after quality con-
trols at the Laboratoire National de Santé in Bamako,
Mali. Two cross-sectional surveys were performed. The
first survey was performed in May 2007 a few months
after the start of the IPTi-implementation, but before
the start of the transmission season to collect baseline
prevalence of the molecular markers of SP resistance.
The second cross-sectional survey was conducted after
one year of implementation in December 2007 after the
end of the transmission season, to assess the impact of
IPTi on the selection of SP-resistant dhfr and dhps
mutations in P. falciparum. Children aged 0-5 years ran-
domly selected in each of the health sub-districts were
screened for malaria parasitaemia using thick smears
obtained by finger pricking. Filter paper blood dots were
also collected at the same time for the analysis of SP
resistance molecular markers.
Laboratory methods
Thick smears were Giemsa-stained and examined by
microscopy. Parasite density was determined by count-
ing parasites against 300 leucocytes using a conversion
factor of 25, based on an assumed leukocyte count of
7,500/μl. Filter papers samples were air-dried and stored
at room temperature in labeled individual envelopes.
Preliminary genotyping of one hundred samples demon-
strated that samples with a parasitaemia less than 500
parasites/μl did not consistently yield PCR product.
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P. falciparum mono-infection parasitaemia greater or
equal to 500 asexual stages per μlo fb l o o dw e r ea n a -
lysed by PCR for dhfr and dhps point mutations.
Because of a higher than expected number P. falciparum
mono-infection positive samples, 427 samples of the
baseline survey and 923 samples of end of one year
implementation survey were randomly selected and
tested by PCR. Of the 427 baseline survey samples, 274
samples (150 in the intervention zone and 124 in the
non-intervention zone) were successfully genotyped for
all three dhfr and two dhps mutations, while the remain-
ing were successfully tested for one, two, three or four
mutations. Of the 923 randomly selected samples of end
of one-year implementation survey, 742 samples (379 in
the intervention zone and 363 in the non-intervention
zone) were successfully genotyped for all three dhfr and
two dhps mutations, and the remaining for one, two,
three or four mutations.
A simple DNA extraction method for filter paper
strips was used [22]. Briefly, approximately 1 × 2 mm
piece of blood-soaked filter paper was placed in 50 μlo f
methanol for 15 min. The methanol was poured off and
the paper heated at 95-100°C in 50 μlo fw a t e rf o r1 0
minutes. Five microliters of the resulting solution was
used as PCR template for the first round of the Nested
PCR. One microliter of the product of the first PCR was
amplified in the second round of PCR. Samples that
failed to yield PCR amplification with the methanol
method were re-extracted using an alternative chelex-
based method [23]. Dhfr and dhps genotypes were deter-
mined using nested mutation-specific PCR and/or PCR-
RFLP according to published methods [16,23]. Dhfr
mutations at codons 51, 59 and 108 and dhps mutations
at codons 437 and 540 were analysed. One third of the
PCR gels were examined by a senior scientist external to
the study. The conformity of the gels with standard cri-
teria for PCR gel validation and the fidelity of the tran-
scription of lab notebook (source documents) with
electronic files were checked. Error cases were corrected
and PCR analyses repeated as needed.
Study endpoints
The primary endpoint was the frequency of quadruple
mutant of molecular markers (dhfr 51, 59 and 108 and
dhps 437) after one year of IPTi implementation. Sec-
ondary endpoints were the frequencies of single muta-
t i o n sa sw e l la st h et r i p l em u t a n t s( dhfr 51 + 59 + 108)
determined by PCR at the end of one year of implemen-
tation and frequencies of these individual and multiples
dhfr and dhps mutations at baseline. The frequency of a
particular mutant was calculated as the proportion of
the specific mutant samples among the total number of
samples successfully analysed for this mutation. Simi-
larly, the frequencies of triple, quadruple and quintuple
mutants were determined as the proportion of subjects
with the three, four and five mutations among the total
numbers of samples tested for the each.
Sample size
Assuming a proportion of the primary endpoint (quad-
ruple mutants, dhfr 51, 59 and 108 and dhps 437) of 8%
in control zone and 14% in IPTi intervention zone, one
side p-value 0.025, a power of 80%, and inter class cor-
relation using 0.01, a sample size of 380 children with
positive parasitaemia in each group with a minimum of
22 subjects and average of 35 subjects per cluster were
n e e d e d .A s s u m i n gap r e v a l e n c eo fP. falciparum parasi-
taemia of 35% and about 10% lost or unsuccessful sam-
ples, about 110 subjects were need to be screened per
cluster resulting in a total of 2,420 children for the two
arms.
Statistical analysis
Cases of mixed infection (wild type and mutant) were
categorized as mutant throughout the analysis. Preva-
l e n c eo fs i n g l em u t a t i o n sa sw e l la st h et r i p l em u t a n t
(dhfr 51 + 59 + 108) and quadruple mutant (triple
mutant + dhps 437) genotypes were determined and
compared between the IPTi implementation and control
zones with 95% confidence intervals around the odds
ratios adjusted for non-independence within health sub-
districts using cluster option in Stata (version 9, Hous-
ton Texas USA). Proportions of categorical variables
were compared using Pearson’s Chi square test. Student
t test was used for the comparison of mean ages and
Mann-Whitney test for the comparison of parasite den-
sities between the two zones.
Ethical considerations
Ethical clearance was obtained from the Ethical Com-
mittee of the Faculty of Medicine Pharmacy and Dentis-
try of the University of Bamako, Mali, and written
informed consent from a parent or legal guardian was
obtained prior to the enrollment of the child in the
survey.
Results
Prevalence of dhfr and dhps mutations at baseline survey
A total of 2,437 subjects were screened (1,213 in the
intervention zone and 1,224 in the non-intervention
zone). Among these, 1,157 subjects (573 in the interven-
tion zone and 584 in the non-intervention zone) had P.
falciparum parasitaemia and 858 (429 in each zone)
with parasitaemia equal or above 500/μl were selected.
Characteristics of subjects enrolled are presented in
Table 1. There were no significant differences between
the two groups in terms of age, parasite prevalence,
parasite density, and prevalence of parasitaemia equal or
above 500/μl.
Prevalence of individual mutations, triple and quadru-
ple mutations in intervention and non-intervention
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dhfr and dhps mutations and triple dhfr mutation were
similar between the intervention and non-intervention
zones. The quadruple mutation was present in 9.2% of
all the samples with similar frequency in the two zones
(10.3% in the intervention zone and 8.1% in the non-
intervention zone).
Prevalence of dhfr and dhps mutations after one year of
IPTi implementation
A total of 2,453 subjects were screened (1,227 in the
intervention zone and 1,226 in the non-intervention
zone). Among these, 1,693 (855 in the intervention zone
and 838 in the non-intervention zone) had P. falciparum
parasitaemia and 1,490 (735 in the intervention zone
and 755 in the non-intervention zone) had P. falciparum
parasitaemia equal or above 500/μl. Characteristics of
children sampled in the two zones are presented in
Table 3. There were no significant differences between
the two groups in terms of age, parasite prevalence,
parasite density and prevalence of parasitaemia equal or
above 500/μl.
Prevalence of individual dhfr and dhps mutations as
well as multiple mutations (dhfr triple mutation and
quadruple mutation (triple +dhps 437)) are presented in
Table 4. There were no significant differences in the fre-
quency of individual mutations between intervention
and non-intervention zones. About half of the children
harboured one of three dhfr mutations in both the inter-
vention and non-intervention zones with a frequency of
the triple dhfr mutation of 38.5% in the intervention
zone compared to 44.8% in the control zone. About
20% of the children with parasitaemia in each zone were
positive for parasites with the mutation 437 on dhps
while only about 1% harboured parasites with the dhps
540 mutation. Similar patterns were found when the
analysis was done by age categories for 2-24 months
and 25-60 months.
T h ep r e v a l e n c eo ft h eq u a d r u p l em u t a n t sw a sa l s o
similar between the two zones: 11.6% in the intervention
zone versus 11.2% in the control zone, odd ratio = 1.04
(95% CI 0.51-2.12) p = 0.90 (Table 4). When the data
were analysed by age categories, similar frequencies of
quadruple mutants were found in the two zones in chil-
dren aged 2-24 months; 9.9% (14/142) in the interven-
tion group versus 8.2% (12/147) in the control group (p
= 0.62). The corresponding figures in children aged 25-
60 months were 12.9% (29/236) in the intervention
group and 13.2% (29/219) in the control group (p =
0.76).
Three of the overall 742 samples (0.8%) successfully
genotyped for all three dhfr and two dhps, harboured
quintuple mutants; all three in the non-intervention
zone, with one in the younger age group (less or equal
to 24 months) and the other two in the older age group
(25-60 months).
Discussion
This study showed no difference between intervention
and non-intervention zones in the frequency of indivi-
dual mutants in the dhfr and dhps genes, as well as in
the triple dhfr and quadruple dhfr dhps mutants, sug-
gesting that the implementation of IPTi with SP for one
year does not result in an increase in the frequency of
these molecular markers at the community level. This is
consistent with the predictions using mathematical
modelling that have indicated that IPTi is unlikely to
appreciably shorten the useful life of the drug used [20],
Table 1 Characteristics of subjects enrolled in the IPTi
intervention and non-intervention zone in Kolokani in
May 2007.
No IPTi IPTi p
Number screened 1224 1213
Mean age (months) 34.1 32.9 0.15
Gender (Male) (%) 53.4 50.9 0.21







Table 2 Prevalence of molecular markers associated with P. falciparum resistance to SP in IPTi intervention and non-
intervention zone in Kolokani at baseline in May 2007.
No IPTi IPTi p
Molecular Markers n Prevalence n Prevalence
DHPS 437 333 20.1% 315 17.5% 0.39
DHPS 540 265 0.4% 313 1.6% 0.22
DHFR 51 209 35.4% 216 38.4% 0.52
DHFR 59 220 48.2% 206 47.6% 0.90
DHFR 108 223 43.0% 242 38.0% 0.27
Triple DHFR mutation 179 34.6% 184 35.8% 0.81
Quadruple mutation 161 8.1% 174 10.3% 0.47
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tant parasites in areas where partial resistance is already
established [13] as it is the case in Mali and in many
countries in sub-Saharan Africa. A small scale placebo-
controlled randomized trial of IPTi with SP in Mozam-
bican children [21] found no difference in the frequency
of dhfr and dhps mutations during the episodes of clini-
cal malaria that occurred two months after the last dose
of IPTi. Another study [24] found a higher frequency of
infections exhibiting four mutations in dhfr and dhps in
children of nine months of age, after a single dose of SP
compared to those in the control group, but no differ-
ence in the rate of infections with isolates with less than
four mutations between the two groups. Other small
scale placebo-control randomized studies of IPT in chil-
dren (IPTc) during a highly seasonal malaria transmis-
sion season did not find differences in the frequency of
dhfr and dhps mutations [25] or in vivo response to SP
[26] between those who received IPT with SP versus
those who did not. Similar frequency of the dhfr triple
mutant among antennal care attendees of early gestation
who had not received IPT and delivering women who
h a dr e c e i v e dI P Tw i t hS Pi np r e g n a n c y( I P T p )w a s
reported in a study in Ghana [18]. As estimated in
mathematical models, the drug pressure resulting from
IPTi may be relatively small [20] and there is no evi-
dence that IPT will lead to increased resistance to SP
that could jeopardize the use of the strategy in many
countries in sub-Saharan Africa. However, this study has
assessed the impact of IPTi on molecular markers of SP
resistance after only one year of implementation, and
continuous monitoring of resistance to SP (both mole-
cular and in vivo) would be warranted once IPT is to be
implemented as policy for longer periods of time. Possi-
ble limitations of this study include i) potential bias due
to the difference in the spread of resistance between this
study target population (children between 0-5 years of
age) and the IPTi target population (children less than
one year of age), however the sub-groups analysis did
n o ts h o w na n yd i f f e r e n c eb e t w e e nt h et w oz o n e si nt h e
children 2-24 months at the time of the second cross-
sectional survey, targeted by the intervention and ii) the
possibility of cross-contamination between intervention
and non-intervention zones. However, the use of IPTi in
non-intervention zones is unlikely to bias our results as
only a very small proportion (less than 1%) of children
0-23 months had received IPTi in the non-intervention
zone, and a high coverage of IPTi (>90% based on
health records) was achieved in the intervention zone.
Furthermore, the frequency of quadruple mutants at
baseline was 10.3% compared to 11.6% at the end of
first year of intervention and 8.1% compared to 11.2% in
the control group. Rapid selection under drug pressure
Table 3 Characteristics of subjects enrolled in the IPTi
intervention and non-intervention zone in Kolokani in
December 2007 after one year of implementation.
No IPTi IPTi p
Number screened 1226 1227
Mean age (months) 32.9 33.0 0.96
Gender (Male) (%) 51.3 50.3 0.63
Parasite prevalence (%) 71.5 73.3 0.32
Median parasitaemia (per μl) 3325 3850 0.06
Prevalence of parasitaemia ≥
500/μl (%)
62.7 64.8 0.31
Table 4 Prevalence of molecular markers associated with P. falciparum resistance to SP in IPTi intervention and non-
intervention zone in Kolokani in December 2007 after one year of implementation.
No IPTi IPTi OR 95% CI p








1.15 0.59- 2.24 0.68
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has been reported [27]. However, in the absence of
structured P. falciparum populations, the flow of para-
sites between areas that are very close could have
diluted P. falciparum populations that were selected
under SP pressure in the intervention zones by unse-
lected P. falciparum populations coming from non-
intervention zones [28]. The use of threshold parasitae-
mia equal or above 500/μl is unlikely to bias our results
since the prevalence of parasitaemia above this threshold
was similar between the two zones, and it is unlikely
that mutants parasite were more prevalent below this
threshold in one zone compared to other.
In line with other studies in Mali and countries in
West Africa [29-32], this study shows relatively high
levels of individual dhfr mutations in the study area
with half of the parasitemic children harbouring mutant
genotypes and a prevalence of triple mutations of 44.5%.
This may reflect the long history of usage of sulpha
drugs including SP across the countries. Although the
dhfr triple mutation was prevalent in 34.6 to 44.8% of
infections, it is well established that this genotype does
not correlate with in vivo SP failure in West Africa
[31-33]. The quadruple mutation genotype most asso-
ciated with in vivo SP failure in Mali (our unpublished
data) and in Ghana [33] was similar between the two
zones and present in about 11% of infections in overall
at the end of one year of implementation. This is also
consistent with rates for this genotype found by us in
various parts of Mali and by others in the West African
sub-region [31,34,35]. Similar to other reports from the
sub-region, the dhps 540E was very rare in this study
[31,33]. However, here are reported the first cases of
dhps 540E found in Mali.
In conclusion, this study shows low prevalence of
quadruple mutants (triple dhfr mutants + dhps 437G)
associated with in vivo resistance to SP in Mali and no
evidence of increased frequency of molecular markers of
SP resistance in areas where IPTi was implemented for
one year.
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